PHILADELPHIA POSITIVE ACUTE LYMPHOCYTIC LEUKAEMIA

This adverse event was reported 163 times

These drugs are most commonly taken by patients reporting PHILADELPHIA POSITIVE ACUTE LYMPHOCYTIC LEUKAEMIA:

# Drug Count
0 DASATINIB 30
1 PONATINIB HYDROCHLORIDE 26
2 METHOTREXATE SODIUM 24
3 PREDNISONE 24
4 METHOTREXATE 22
5 CYTARABINE 20
6 CYCLOPHOSPHAMIDE 17
7 CYCLOPHOSPHAMIDE FOR INJECTION 17
8 CYCLOPHOSPHAMIDE INJECTION, SOLUTION 17
9 IMATINIB 16
See all common drugs associated with PHILADELPHIA POSITIVE ACUTE LYMPHOCYTIC LEUKAEMIA

PHILADELPHIA POSITIVE ACUTE LYMPHOCYTIC LEUKAEMIA is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 PONATINIB HYDROCHLORIDE 26 0.0050
1 DASATINIB 30 0.0032
2 INOTUZUMAB OZOGAMICIN 6 0.0020
3 DAUNORUBICIN HYDROCHLORIDE 2 0.0012
4 ASCIMINIB 4 0.0011
5 BLINATUMOMAB 8 0.0007
6 AMIKACIN SULFATE 1 0.0006
7 MITOXANTRONE HYDROCHLORIDE 3 0.0005
8 RASBURICASE 1 0.0004
9 CYTARABINE 20 0.0003
See all drugs enriched for association with PHILADELPHIA POSITIVE ACUTE LYMPHOCYTIC LEUKAEMIA

PHILADELPHIA POSITIVE ACUTE LYMPHOCYTIC LEUKAEMIA is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 CD22-directed Immunoconjugate [EPC] 6 0.0020
1 Antifibrinolytic Agent [EPC] 2 0.0002
2 Osmotic Diuretic [EPC] 1 0.0002
3 Echinocandin Antifungal [EPC] 1 0.0001
4 Substance P/Neurokinin-1 Receptor Antagonist [EPC] 1 0.0001
5 BCL-2 Inhibitor [EPC] 7 0.0001
6 Azole Antifungal [EPC] 15 0.0001
7 Nucleoside Metabolic Inhibitor [EPC] 21 0.0001
8 Asparagine-specific Enzyme [EPC] 1 0.0001
9 Alkylating Drug [EPC] 17 0.0001
See all drug classes enriched for association with PHILADELPHIA POSITIVE ACUTE LYMPHOCYTIC LEUKAEMIA